Literature DB >> 24361787

Secondary analyses from a randomized clinical trial: age as the key prognostic factor in endometrial carcinoma.

Pierluigi Benedetti Panici1, Stefano Basile2, Maria Giovanna Salerno3, Violante Di Donato1, Claudia Marchetti1, Giorgia Perniola1, Antonio Palagiano1, Alessandra Perutelli3, Francesco Maneschi4, Andrea Alberto Lissoni5, Mauro Signorelli5, Giovanni Scambia6, Saverio Tateo7, Giorgia Mangili8, Dionyssios Katsaros9, Elio Campagnutta10, Nicoletta Donadello11, Stefano Greggi12, Mauro Melpignano13, Francesco Raspagliesi14, Gennaro Cormio15, Roberto Grassi16, Massimo Franchi17, Diana Giannarelli18, Roldano Fossati19, Valter Torri19, Clara Crocè20, Costantino Mangioni5.   

Abstract

OBJECTIVE: The purpose of this study was to explore in greater depth the outcomes of the Italian randomized trial investigating the role of pelvic lymphadenectomy in clinical early stage endometrial cancer. In the attempt to identify the patients with poorer prognosis, the impact of age and body mass index were also thoroughly investigated by cancer-specific survival (CSS) analyses. STUDY
DESIGN: Survival outcomes of trial patients were analyzed in relation to age (≤65 years and >65 years) in the 2 arms (lymphadenectomy and no lymphadenectomy) and in the whole population of the trial.
RESULTS: Univariate and multivariable analyses of CSS and overall survival (OS) of patients showed that age >65 years is a strong independent poor prognostic factor (5-y OS 92.1% and 78.4% in ≤65 years and >65 years patients, respectively, P < .0001; 5-y CSS 93.8% and 83.5% in ≤65 years and >65 years patients, respectively, P = .003). Among women ≤65 years, node negative patients had 94.4% 5-y OS and 96.3% 5-y CSS vs 74.3% 5-y OS and 74.3% 5-y CSS for node positive patients (P = .009 and P = .002, respectively), while among women >65 y, node negative patients had 75.7% 5-y OS and 83.6% 5-y CSS vs 74.1% 5-y OS and 83.3% 5-y CSS for node positive patients (P = .55 and P = .58, respectively). Univariate and multivariable survival analyses in the whole trial population showed that older age, and higher tumor grade and stage were significantly associated to a worse prognosis.
CONCLUSION: Older women faced an intrinsic poorer survival whether or not they underwent lymphadenectomy, and, unexpectedly, irrespective of the presence of nodal metastasis. Only in older patients was obesity (body mass index >30) significantly associated with scarce prognosis.
Copyright © 2014 Mosby, Inc. All rights reserved.

Entities:  

Keywords:  age; body mass index; endometrial carcinoma; prognostic factors

Mesh:

Year:  2013        PMID: 24361787     DOI: 10.1016/j.ajog.2013.12.025

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  18 in total

1.  Prognostic value of cyclin B in endometrial endometrioid adenocarcinoma.

Authors:  Simi Santala; Anne Talvensaari-Mattila; Ylermi Soini; Markku Santala
Journal:  Tumour Biol       Date:  2014-10-15

2.  Is Adjuvant Chemotherapy Necessary in Patients with Early Endometrial Cancer?

Authors:  Yuki Iida; Hiroaki Komatsu; Masayo Okawa; Daiken Osaku; Kanae Nosaka; Shinya Sato; Tetsuro Oishi; Fuminori Taniguchi; Tasuku Harada
Journal:  Yonago Acta Med       Date:  2022-02-22       Impact factor: 1.641

3.  Evaluation of postoperative chemotherapy in patients with uterine carcinosarcoma: a retrospective survey of the Tohoku Gynecologic Cancer Unit.

Authors:  Ai Otsuki; Takeo Otsuki; Hideki Tokunaga; Hitoshi Niikura; Satoru Nagase; Takashi Sugiyama; Masafumi Toyoshima; Hiroki Utsunomiya; Yoshihito Yokoyama; Hideki Mizunuma; Naoki Sato; Yukihiro Terada; Tadahiro Shoji; Toru Sugiyama; Kenji Nakahara; Tsuyoshi Ohta; Hidekazu Yamada; Toru Tase; Hiroshi Nishiyama; Keiya Fujimori; Tadao Takano; Fumiaki Takahashi; Yoh Watanabe; Nobuo Yaegashi
Journal:  Int J Clin Oncol       Date:  2014-07-18       Impact factor: 3.402

4.  Associations between etiologic factors and mortality after endometrial cancer diagnosis: the NRG Oncology/Gynecologic Oncology Group 210 trial.

Authors:  Ashley S Felix; D Scott McMeekin; David Mutch; Joan L Walker; William T Creasman; David E Cohn; Shamshad Ali; Richard G Moore; Levi S Downs; Olga B Ioffe; Kay J Park; Mark E Sherman; Louise A Brinton
Journal:  Gynecol Oncol       Date:  2015-09-01       Impact factor: 5.482

Review 5.  Lymphadenectomy for the management of endometrial cancer.

Authors:  Jonathan A Frost; Katie E Webster; Andrew Bryant; Jo Morrison
Journal:  Cochrane Database Syst Rev       Date:  2017-10-02

6.  High-Grade Endometrial Cancer-Behaviour and Outcomes at a Tertiary Cancer Centre.

Authors:  Prerna Lakhwani; Priya Agarwal; Ashish Goel; Nidhi Nayar; Pankaj Pande; Kapil Kumar
Journal:  Indian J Surg Oncol       Date:  2019-08-21

7.  Lymphadenectomy in women with endometrial cancer: aspiration and reality from a radiation oncologist's point of view.

Authors:  Robert Foerster; Robert Kluck; Nathalie Arians; Stefan Rieken; Harald Rief; Sebastian Adeberg; Tilman Bostel; Ingmar Schlampp; Juergen Debus; Katja Lindel
Journal:  Radiat Oncol       Date:  2015-07-16       Impact factor: 3.481

8.  Bilateral femur metastases in low-grade endometrial carcinoma.

Authors:  Pierre Lunardi; Fabien Vidal; Franck Accadbled; Pierre Leguevaque; Marc Soule-Tholy; Jean Baptiste Beauval; Stéphanie Motton
Journal:  Clin Case Rep       Date:  2015-05-25

9.  Implications of a two-step procedure in surgical management of patients with early-stage endometrioid endometrial cancer.

Authors:  Emmanuelle Arsène; Géraldine Bleu; Benjamin Merlot; Loïc Boulanger; Denis Vinatier; Olivier Kerdraon; Pierre Collinet
Journal:  J Gynecol Oncol       Date:  2015-04       Impact factor: 4.401

10.  A critical assessment on the role of sentinel node mapping in endometrial cancer.

Authors:  Giorgio Bogani; Antonino Ditto; Fabio Martinelli; Mauro Signorelli; Stefania Perotto; Domenica Lorusso; Francesco Raspagliesi
Journal:  J Gynecol Oncol       Date:  2015-10-08       Impact factor: 4.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.